In the News
169 articles
Pancreatic Cancer Research Updates from ASCO 2024
Learn about the latest developments in pancreatic cancer research into immunotherapy and chemotherapy from the ASCO 2024 meeting.
Looking Back at the Year in Research: 2019
Research highlights of 2019 include: approval of a PARP inhibitor, artificial intelligence to diagnose pancreatic cysts, and updated radiation guidelines.
Research Updates from ASCO GI 2023
Read the latest clinical trial and research updates from the 2023 ASCO GI meeting, including a review of genetic testing uptake.
Pancreatic Cancer Science—2021 in Review
As the year winds down Let’s Win provides an overall look at the highlights of 2021 in pancreatic cancer science.
The American Association for Cancer Research (AACR) Virtual Special Conference: Pancreatic Cancer Day One
Let’s Win and the Lustgarten Foundation present highlights of Day One of the AACR Virtual Special Conference on Pancreatic Cancer.
A Liquid Biopsy for Pancreatic Cancer
Dr. Bert Vogelstein and his team at Johns Hopkins are working with a blood test called a liquid biopsy, which tests cells for mutations related to cancer.
Progress and Promise—Research in 2023
What advances were made in 2023 for pancreatic cancer treatments? Where is research headed in the coming year?
Accessing Daraxonrasib: A Quick Primer
Daraxonrasib, the first KRAS drug for pancreatic cancer, is now available through an expanded access program, but your physician must apply for you.
AACR Special Conference Highlights Advances in Pancreatic Cancer Research
Here are some of the most interesting highlights from the 2024 AACR Special Conference on Pancreatic Cancer Research.
ASCO GI Symposium Features a Broad Range of Pancreatic Cancer Research
Researchers at ASCO GI 2024 reported on research in health disparities, KRAS and other genetic mutations, and novel treatments.
NAPOLI-3 Trial Meets Primary Endpoint in Metastatic Disease
Dr. Tanios Bekaii-Saab explains the early positive results from the NAPOLI-3 clinical trial, testing the NALIRIFOX combination.
A Year in Review: 2020
In March 2020, life as we knew it changed. The way we work, the way we gather, the way we each live our daily lives all felt upended, seemingly overnight. The global pandemic of COVID-19 affected everything, including cancer care and research. COVID-19 brought new risks to cancer patients, whose immune systems are compromised from […]
Cracking the KRAS Code
Dr. Despina Siolas is focusing her research on new treatments for pancreatic cancer, particularly ones that go after KRAS mutations.
Putting the Immune System on the Offensive
A discussion of immunology in cancer treatment, focusing on the work of Elizabeth Jaffe, M.D., and her cancer vaccine and checkpoint inhibitors.
ASCO 2026: An Update on Research
Daraxonrasib wasn’t the only research news to come out at ASCO 2026. Learn about other new drugs and tests for pancreatic cancer.